相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Brown and beige fat: development, function and therapeutic potential
Matthew Harms et al.
NATURE MEDICINE (2013)
O-GlcNAc modification of PPARγ reduces its transcriptional activity
Suena Ji et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
Brown Remodeling of White Adipose Tissue by SirT1-Dependent Deacetylation of Pparγ
Li Qiang et al.
CELL (2012)
Fibroblast Growth Factor-21 Regulates PPARγ Activity and the Antidiabetic Actions of Thiazolidinediones
Paul A. Dutchak et al.
CELL (2012)
PPARγ agonists Induce a White-to-Brown Fat Conversion through Stabilization of PRDM16 Protein
Haruya Ohno et al.
CELL METABOLISM (2012)
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials
G. Musso et al.
DIABETOLOGIA (2012)
Thiazolidinedione safety
Jacqueline Kung et al.
EXPERT OPINION ON DRUG SAFETY (2012)
Adipocyte NCoR Knockout Decreases PPARγ Phosphorylation and Enhances PPARγ Activity and Insulin Sensitivity
Pingping Li et al.
CELL (2011)
Acetylation and nuclear receptor action
Chenguang Wang et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2011)
Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation
Jang Hyun Choi et al.
NATURE (2011)
Chronic Peroxisome Proliferator-activated Receptor γ (PPARγ) Activation of Epididymally Derived White Adipocyte Cultures Reveals a Population of Thermogenically Competent, UCP1-containing Adipocytes Molecularly Distinct from Classic Brown Adipocytes
Natasa Petrovic et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARγ by Cdk5
Jang Hyun Choi et al.
NATURE (2010)
MBX-102/JNJ39659100, a Novel Peroxisome Proliferator-Activated Receptor-Ligand with Weak Transactivation Activity Retains Antidiabetic Properties in the Absence of Weight Gain and Edema
Francine M. Gregoire et al.
MOLECULAR ENDOCRINOLOGY (2009)
PPAR-γ AF-2 Domain Functions as a Component of a Ubiquitin-dependent Degradation Signal
Gail E. Kilroy et al.
OBESITY (2009)
Fat and beyond: The diverse biology of PPAR gamma
Peter Tontonoz et al.
ANNUAL REVIEW OF BIOCHEMISTRY (2008)
Role of peiroxisome proliferators-activated receptors in the pathogenesis and treatment of nonaloholic fatty liver disease
Eric R. Kallwitz et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2008)
Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatly acid oxidation in moderately obese men
Ulf Riserus et al.
DIABETES (2008)
Concepts in sumoylation: a decade on
Ruth Geiss-Friedlander et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2007)
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis
Glen Lutchman et al.
HEPATOLOGY (2007)
Macrophage-specific PPARγ controls alternative activation and improves insulin resistance
Justin I. Odegaard et al.
NATURE (2007)
Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones
Andrea L. Hevener et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Prediction of Nε-acetylation on internal lysines implemented in Bayesian Discriminant Method
Ao Li et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor γ function (P465L PPARγ) in mice
Sarah L. Gray et al.
DIABETES (2006)
Peroxisome proliferator-activated receptor γ recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis
Irena Iankova et al.
MOLECULAR ENDOCRINOLOGY (2006)
An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARγ, adipogenesis, and insulin-responsive hexose transport
XQ Tang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
PDSM, a motif for phosphorylation-dependent SUMO modification
V Hietakangas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ
G Pascual et al.
NATURE (2005)
Dysregulation of the peroxisome proliferator-activated receptor target genes by XPD mutations
E Compe et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Benzoyl 2-methyl indoles as selective PPARγ modulators
JJ Acton et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2005)
PPARs and the complex journey to obesity
RM Evans et al.
NATURE MEDICINE (2004)
The transactivating function of peroxisome proliferator-activated receptor γ is negatively regulated by SUMO conjugation in the amino-terminal domain
D Yamashita et al.
GENES TO CELLS (2004)
Peroxisome proliferator-activated receptor γ in diabetes and metabolism
SM Rangwala et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2004)
Principles for modulation of the nuclear receptor superfamily
H Gronemeyer et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Adipose-specific peroxisome proliferator-activated receptor γ knockout causes insulin resistance in fat and liver but not in muscle
WM He et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Activation of peroxisome proliferator-activated receptor δ induces fatty acid β-oxidation in skeletal muscle and attenuates metabolic syndrome
T Tanaka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Muscle-specific Pparg deletion causes insulin resistance
AL Hevener et al.
NATURE MEDICINE (2003)
Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity
SM Rangwala et al.
DEVELOPMENTAL CELL (2003)
Liver peroxisome proliferator-activated receptor γ contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass
O Gavrilova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Differential effects of rosiglitazone on skeletal muscle and liver insulin resistance in A-ZIP/F-1 fatless mice
JK Kim et al.
DIABETES (2003)
Distinct properties and advantages of a novel peroxisome proliferator-activated protein γ selective modulator
JP Berger et al.
MOLECULAR ENDOCRINOLOGY (2003)
Human metabolic syndrome resulting from dominant-negative mutations in the nuclear receptor peroxisome proliferator-activated receptor-γ
DB Savage et al.
DIABETES (2003)
Liver-specific disruption of PPARγ in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes
K Matsusue et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
PPARG F388L, a transactivation-deficient mutant, in familial partial lipodystrophy
RA Hegele et al.
DIABETES (2002)
Peroxisome proliferator-activated receptor-γ in macrophage lipid homeostasis
CH Lee et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2002)
A futile metabolic cycle activated in adipocytes by antidiabetic agents
HP Guan et al.
NATURE MEDICINE (2002)
Role of peroxisome proliferator-activated receptor-γ in maintenance of the characteristics of mature 3T3-L1 adipocytes
Y Tamori et al.
DIABETES (2002)
Interferon-γ-mediated activation and ubiquitin-proteasome-dependent degradation of PPARγ in adipocytes
ZE Floyd et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes
AB Mayerson et al.
DIABETES (2002)
Endogenous glucose production is inhibited by the adipose-derived protein Acrp30
TP Combs et al.
JOURNAL OF CLINICAL INVESTIGATION (2001)
Mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ (PPARγ) deficiency and PPARγ agonist improve insulin resistance.
T Yamauchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity
T Yamauchi et al.
NATURE MEDICINE (2001)
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
AH Berg et al.
NATURE MEDICINE (2001)
A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport
WR Oliver et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
The hormone resistin links obesity to diabetes
CM Steppan et al.
NATURE (2001)
Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones
L Chao et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(δ)
JM Peters et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation
S Hauser et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
A PPARγ mutant serves as a dominant negative inhibitor of PPAR signaling and is localized in the nucleus
J Berger et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2000)
Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency
PDG Miles et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
分享论文
